- Home
- WHWK vs PRLD Comparison
WHWK vs PRLD Comparison
Compare WHWK & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- PRLD
- Stock Information
- Founded
- WHWK 2007
- PRLD 2016
- Country
- WHWK United States
- PRLD United States
- Employees
- WHWK N/A
- PRLD N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- WHWK Health Care
- PRLD Health Care
- Exchange
- WHWK Nasdaq
- PRLD Nasdaq
- Market Cap
- WHWK 48.3M
- PRLD 50.1M
- IPO Year
- WHWK N/A
- PRLD 2020
- Fundamental
- Price
- WHWK $1.87
- PRLD $1.03
- Analyst Decision
- WHWK
- PRLD Strong Buy
- Analyst Count
- WHWK 0
- PRLD 2
- Target Price
- WHWK N/A
- PRLD $4.50
- AVG Volume (30 Days)
- WHWK 100.5K
- PRLD 152.5K
- Earning Date
- WHWK 05-08-2025
- PRLD 05-06-2025
- Dividend Yield
- WHWK N/A
- PRLD N/A
- EPS Growth
- WHWK N/A
- PRLD N/A
- EPS
- WHWK 0.91
- PRLD N/A
- Revenue
- WHWK $27,775,000.00
- PRLD $7,000,000.00
- Revenue This Year
- WHWK $40.15
- PRLD N/A
- Revenue Next Year
- WHWK N/A
- PRLD N/A
- P/E Ratio
- WHWK $2.01
- PRLD N/A
- Revenue Growth
- WHWK 16.51
- PRLD N/A
- 52 Week Low
- WHWK $1.21
- PRLD $0.61
- 52 Week High
- WHWK $3.81
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- WHWK N/A
- PRLD 61.05
- Support Level
- WHWK N/A
- PRLD $0.93
- Resistance Level
- WHWK N/A
- PRLD $1.00
- Average True Range (ATR)
- WHWK 0.00
- PRLD 0.09
- MACD
- WHWK 0.00
- PRLD 0.01
- Stochastic Oscillator
- WHWK 0.00
- PRLD 96.28
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.